alex's profileWords to be ReadPhotosBlogListsMore  |  Tools Help |
|
15 November MedSpas of America Expands Skin Care Presence
MedSpas of America, Atlanta, GA, has begun its expansion into the skin care products market. A consumer branded products company on the rise, MedSpas sees a large potential in the aging “baby boomer” segment and is preparing to tap the wrinkles that it will almost certainly provide. The baby boomer generation has a vast pool of disposable money and is very willing to spend if it means keeping the aging process at bay. With this in mind, the company has placed its focus on the “high end “ consumer and foresees positive returns as the new expansion program is rolled out. Two new branded product lines are scheduled to be introduced, at the end of the first quarter 2008, to take advantage of two distinct skin care segments. The company’s Natural Renu line will offer retail skincare products, with an emphasis on internet sales, while its doceuticals line will be offered to professional skin care providers such as physicians and aestheticians. Offering the two product lines in this fashion effectively positions the company on both sides of the skin care market (retail and professional) and readies it to take a solid portion of the $5.4 billion cosmeceuticals market. MedSpas of America anticipates that this expansion will increase company revenues in excess of 100% and follow the segments annual growth of approximately 8.5%. An end of the first quarter rollout appears optimally timed to begin taking advantage of day spas continuing quick penetration of higher and middle income segments. In the past, spas may have been thought to be a luxury. Today, they are though of as a need, to stay relaxed in a stressful world. MedSpas of America is positioned to sooth and smooth those in need. CardioVascular Biotherapeutics Inc. Moves Closer to Topical Diabetic Wound Care Rollout
Investing in the pharmaceutical world means trying to invest as a product gets closer to completing FDA trials and approvals. In many respects, this is a wise strategy as a negative review by the FDA can kill a drug and its sponsor right along with it. From another point of view, taking the longer term view and dictating return terms can be a better way of investing if the product and company seem to be moving in the right direction. Generally, this could be thought of as the next quarter syndrome versus the next year(s) reward concept. The first concept got the economy where it is today. The second can hold hope for a larger more controlled return. CardioVascular Biotherapeutics Inc., a biopharmaceutical company, works to develop medications for sever cardiac and wound care conditions. The company is currently beginning Phase II trials for its lead product and continues development in clinical trials for three additional products directed at wound care. By all accounts, the company is making significant progress with its trials and testing. It is currently starting Phase II - severe coronary heart disease - trials for its Fibrobalst 1 (FGF-1 141) product. Although the protein based product is envisioned for increasing blood flow in heart blood vessels, it is thought that other organs will be able to take advantage of its effects as well. The company has been finding excellent successes for several of its wound care drugs as well. The topical protein based treatments have been privately funded to a minimum of $3 million and could reach a maximum of $18 million as warranted. As one might suspect, the company is focusing on the Phase II trials of its coronary protein product, as it is closer to market. The company’s three other products, however, may offer a wider spectrum of user and the potential for longer term returns. Diabetic wound care and various other stasis leg wound issues are a very large market as it is, and have expectation of accelerated growth in the long term. The cardiac product surely will provide solid revues, but it may work out that over the longer term, per patient revenue will tilt toward the wound care product. Derma Life, the current leading funder of the wound care product clinical trials, appears to be viewing the longer term in its investment choices and may surely benefit. If other investors do the same, they may well also be on a straight line to profit when the products make it to market.
|
|
|
